Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksALM.L Regulatory News (ALM)

  • There is currently no data for ALM

Directorate Changes

10 Mar 2020 07:00

RNS Number : 5157F
Allied Minds PLC
10 March 2020
 

10 March 2020

 

Allied Minds

 

Directorate changes

 

Allied Minds plc (LSE: ALM), the IP commercialisation company focused on early stage company development within the technology sector, has appointed Harry Rein, currently Senior Independent Director, as Chairman. He succeeds Jeff Rohr, who has stepped down. Additionally, Bruce Failing has been appointed as Non-Executive Director. Both appointments are with immediate effect.

 

Bruce has over 30 years of management and investment experience in the areas of media and consumer products, applied technology and logistics management. He founded and currently is the General Partner of Alerion Partners. Previously, he was CEO of Productivity Solutions, Electronic Retailing Systems and Actmedia, and Executive Chairman of ScentAir Technologies and Lamaze Publishing & the Newborn Channel. Bruce attended Tufts University (1971) and holds an MBA from Harvard Business School (1973).

 

Bruce will assume the Senior Independent Director role, Chair the Remuneration Committee and be on the Nomination and Audit Committees.

 

Mark Lerdal will Chair the Audit Committee. Harry will Chair the Nomination Committee.

 

Harry Rein, Non-Executive Chairman, commented:

 

"On behalf of the Board, I extend our deepest thanks and appreciation to Jeff for his many dedicated years of service on the Board and the leadership and support he has provided over the past six years. 

 

"I welcome Bruce to the Board. His operational and management experience and expertise is invaluable and positions him perfectly to help us.

 

"I look forward to becoming Chairman and continuing to work closely with my fellow directors as we execute on our strategy of delivering shareholder value by focusing on our existing portfolio."

 

There are no further details in relation to Mr. Failing's appointment which require disclosure pursuant to Listing Rule 9.6.13.

 

For more information, please contact:

 

Allied Minds plc

+1 617 419 1800

IR@alliedminds.com

Instinctif

+44 20 7457 2020

Adrian Duffield / Chantal Woolcock

 

About Allied Minds

Allied Minds plc is an IP commercialisation company focused on early stage company development within the technology sector. With origination relationships that span US federal laboratories, universities, and leading US corporations, Allied Minds historically created, and now operates and funds, a portfolio of companies to generate long-term value for its investors and stakeholders. Based in Boston, Allied Minds supports its businesses with capital, management, expertise and shared services. For more information, please visit www.alliedminds.com.

 

Allied Minds Forward-Looking Statement

This press release contains statements that are or may be forward-looking statements, including statements that relate to Allied Minds' future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in Allied Minds' regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of Allied Minds and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law, regulatory requirement, the Listing Rules and the Disclosure Guidance and Transparency Rules, neither Allied Minds nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

 

This announcement contains inside information as defined in Article 7 of the Market Abuse Regulation No. 596/2014.

 

###

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAUKOKRRSUORAR
Date   Source Headline
31st Jan 20173:55 pmRNSTotal Voting Rights
30th Jan 201712:02 pmRNSPrice Monitoring Extension
3rd Jan 20172:48 pmRNSHolding(s) in Company
3rd Jan 20172:11 pmRNSTotal Voting Rights
13th Dec 20167:00 amRNSFormation of Signature Medical, Inc.
9th Dec 20165:04 pmRNSHolding(s) in Company
7th Dec 20164:34 pmRNSHolding(s) in Company
6th Dec 20165:05 pmRNSHolding(s) in Company
6th Dec 20165:04 pmRNSHolding(s) in Company
2nd Dec 20167:00 amRNSResults of equity placing
1st Dec 20164:50 pmRNSProposed Equity Placing
23rd Nov 20167:00 amRNSHawkEye 360 Raises $11m in Series A Financing
21st Nov 20167:00 amRNSFormation of Vatic Materials, Inc.
18th Nov 20163:15 pmRNSBlock Listing Six Monthly Return
11th Nov 20165:17 pmRNSHolding(s) in Company
24th Oct 20167:00 amRNSPrecision Biopsy Raises $5.0 Million
17th Oct 201612:07 pmRNSSecond Price Monitoring Extn
17th Oct 201612:02 pmRNSPrice Monitoring Extension
29th Sep 20167:00 amRNSAllied Minds & GE Ventures Form Strategic Alliance
8th Sep 201612:02 pmRNSPrice Monitoring Extension
31st Aug 20165:11 pmRNSTotal Voting Rights
25th Aug 20167:00 amRNSHalf-year Report
22nd Aug 20167:00 amRNSAllied Minds Secures $20m Debt Facility from SVB
22nd Aug 20167:00 amRNSAllied Minds' Subsidiary ABLS II Raises $15m
1st Aug 20167:00 amRNSSciFluor Enters Clinical Trial Stage
29th Jul 201610:30 amRNSTotal Voting Rights
13th Jul 201610:02 amRNSDirector/PDMR Shareholding
13th Jul 201610:01 amRNSDirector/PDMR Shareholding
13th Jul 201610:01 amRNSDirector/PDMR Shareholding
13th Jul 201610:00 amRNSDirector/PDMR Shareholding
7th Jul 20167:00 amRNSLong Term Incentive Plan - Listing Application
30th Jun 20167:00 amRNSTotal Voting Rights
22nd Jun 20164:41 pmRNSSecond Price Monitoring Extn
22nd Jun 20164:35 pmRNSPrice Monitoring Extension
14th Jun 20162:38 pmRNSDirector/PDMR Shareholding
13th Jun 20165:18 pmRNSDirector/PDMR Shareholding
31st May 20164:44 pmRNSBlocklisting Six Monthly Return
26th May 20165:23 pmRNSResult of AGM
26th May 20167:00 amRNSAGM Statement
25th May 20167:00 amRNSABLS II Completes Drug Feasibility Programme
13th May 20167:00 amRNSDirector/PDMR Shareholding
10th May 20164:30 pmRNSLong Term Incentive Plan
28th Apr 201612:33 pmRNSHolding(s) in Company
26th Apr 20167:00 amRNSAllied Minds Raises $80m for ABLS Capital
25th Apr 20167:00 amRNSAnnual Financial Report
19th Apr 20167:00 amRNSAppointment of Joint Broker
16th Mar 20167:00 amRNSABLS agrees license with NYU
10th Feb 20164:40 pmRNSSecond Price Monitoring Extn
10th Feb 20164:36 pmRNSPrice Monitoring Extension
9th Feb 20164:40 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.